The addition of a novel genomic classifier (GC) during active surveillance for prostate cancer (PCa) was shown to predict disease progression independently from clinical risk assessment tools such as multiparametric magnetic resonance imaging (mpMRI), according to a recent study presented at the Society of Urologic Oncology (SUO) 25th Annual Meeting. ...